Pan-Coronavirus Immunogenic Composition Using Conserved Antigens
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccines against SARS-CoV-2 and other coronaviruses have limitations, including reduced efficacy against viral variants and limited protection against multiple human coronaviruses.
Innovation Solution
Development of a pan-coronavirus immunogenic composition comprising coronavirus antigenic polypeptides, nucleic acid molecules encoding these polypeptides, monoclonal antibodies, and nucleic acid molecules encoding monoclonal antibodies, with a focus on conserved regions such as the fusion peptide and prefusion stabilized spike protein.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If vaccines target the receptor-binding domain (RBD) to elicit neutralizing antibodies, then neutralizing activity is achieved, but efficacy is reduced against viral variants with mutations in the RBD
Solution Approach 1:
The vaccine composition uses conserved coronavirus antigens (fusion peptide and N-terminal domain) that are universal across multiple coronavirus species, enabling the vaccine to protect against SARS-CoV-2 and other human coronaviruses simultaneously, rather than targeting the variable RBD region
Solution Approach 2:
The invention changes the target parameter from the variable RBD region to the highly conserved fusion peptide and N-terminal domain regions, which maintain similar sequences across different coronavirus variants and species, thereby achieving broader and more reliable protection
2Reliability
If vaccines are designed for specific SARS-CoV-2 strains, then high efficacy against that strain is achieved, but protection against multiple human coronaviruses is limited
Solution Approach 1:
The vaccine composition uses conserved coronavirus antigens (fusion peptide and N-terminal domain) that are universal across multiple coronavirus species, enabling the vaccine to protect against SARS-CoV-2 and other human coronaviruses simultaneously
Solution Approach 2:
The invention combines multiple conserved antigenic regions (fusion peptide and N-terminal domain) from different coronaviruses into a single vaccine composition, creating a multi-functional immunogen that elicits broad cross-protective immunity
3Speed
If viral variants accumulate mutations for improved transmission, then transmissibility increases, but resistance to vaccine-induced immunity develops
Solution Approach 1:
The invention changes the target parameter from the variable RBD region to the highly conserved fusion peptide and N-terminal domain regions, which maintain similar sequences across different coronavirus variants, thereby achieving broader and more reliable protection that does not easily escape through mutation
Data Source
AI summary
The present invention generally relates to immunogenic compositions comprising pan-coronavirus antigenic polypeptides and antibodies, and methods of use thereof for the treatment and prevention of coronavirus infection.